<DOC>
	<DOCNO>NCT00348010</DOCNO>
	<brief_summary>The purpose study compare analgesic effectiveness safety tramadol HCl ER placebo patient moderate severe pain due osteoarthritis ( OA ) . The study hypothesis tramadol HCl ER effective safe treatment OA .</brief_summary>
	<brief_title>A Study Comparing Effectiveness Safety Extended Release Tramadol Versus Placebo Treatment Osteoarthritis ( OA ) Knee</brief_title>
	<detailed_description>Immediate release ( IR ) tramadol demonstrate efficacy several pain condition include : obstetrical , gynecological , orthopedic , abdominal , oral surgery . The short elimination half-life IR tramadol require every 4-6 hour dose maintain optimal level analgesia chronic pain . The study medication study once-daily , extended-release ( ER ) tramadol formulation . This 12-week , multi-center , double-blind , randomize , dose-titration , parallel-group , placebo-controlled study design evaluate analgesic effectiveness safety daily tramadol HCl ER placebo treatment patient OA knee . Patients OA Functional Class I-III knee eligible participation , appropriate criterion meet . After 2-7 day washout period , use analgesic medication use chronic pain management discontinue , patient experience moderate severe pain ( pain intensity &gt; = 40 mm 100 mm visual analog scale ) index knee meet study criterion enter 2-week , double-blind , titration period . During period , patient randomly assign treatment tramadol HCl ER placebo , daily ( QD ) . The initial dose tramadol HCl ER 100 mg match placebo QD . On Day 4 remainder week , patient titrate 200 mg match placebo QD , base tolerability . Beginning Visit 3 , minimum dose 200 mg match placebo QD maintain remainder 12-week study . Patients unable tolerate least 200 mg match placebo QD discontinue study . After Week 1 ( Visit 3 ) , increase 300 mg 400 mg match placebo QD permit , depend adequacy pain relief tolerability side effect . Efficacy safety evaluation collect study visit occur Weeks 1 , 2 , 4 , 8 , 12 early termination . Study medication discontinue Week 12 patient return 1 week post-treatment visit ( Week 13 ) .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Tramadol</mesh_term>
	<criteria>Patients American College Rheumatology ( ACR ) Functional Class IIII OA knee ; involvement least one knee joint warrant treatment NSAIDs , acetaminophen , opioid analgesic least 75 90 day precede screening visit ; patient radiographic evidence osteoarthritis within last 6 month ; patient pain intensity index joint &gt; = 40 mm visual analog scale ( VAS ) baseline visit ; patient able discontinue NSAIDs , COX2 selective inhibitor , analgesic washout period throughout doubleblind study . Patients medical condition , OA , uncontrolled treatment clinically significant condition , investigator 's opinion , precludes study participation interferes assessment chronic pain OA symptom ; patient diagnosis inflammatory arthritis , gout , pseudogout Paget 's disease , , investigator 's opinion , interfere assessment pain symptom OA ; patient diagnosis chronic pain syndrome , patient ACR clinical diagnosis fibromyalgia ; patient clinically significant form joint disease prior joint replacement surgery index joint ; patient anticipate need surgery invasive procedure index joint .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>osteoarthritis</keyword>
	<keyword>knee pain</keyword>
	<keyword>extended release analgesia</keyword>
	<keyword>opioid</keyword>
</DOC>